Abivax SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Marc M. P. de Garidel
- Full Time Employees
- 69
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 7-11 Boulevard Haussmann Paris IF France 75009
- IPO Date
- Jun 26, 2015
- Website
- abivax.com
- Similar Companies
- Business
- Abivax SA engages in the discovery, development, and commercialization of therapeutics that modulate the immune response through the induction of microRNA-124 for the treatment of chronic inflammatory diseases. The company focuses on obefazimod (formerly ABX464), an oral small molecule that enhances miR-124 expression in immune cells to restore cytokine and chemokine homeostasis; its pipeline includes follow-on compounds from a proprietary chemical library targeting additional inflammatory indications. Abivax operates in the biotechnology sector, primarily serving patients with ulcerative colitis and Crohn's disease; it conducts research and development in Montpellier, France, with headquarters in Paris, France, and a U.S. office in Waltham, Massachusetts; founded in 2013, the company targets global markets including North America, Europe, Latin America, and Asia Pacific through clinical trials involving over 600 centers. In July 2025, Abivax completes a $747.5 million public offering, extending its cash runway into Q4 2027 and funding late-stage development; positive top-line results from Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis emerge in Q3 2025, with 44-week maintenance data expected in Q2 2026; patient enrollment begins for the ENHANCE-CD Phase 3 trial in Crohn's disease in Q3 2024, with induction readout anticipated in 2H 2026; post-period debt conversions include Heights Capital Management's EUR 21.9 million and Kreos Capital's Tranche A notes.
Company News
Cedar Grove Capital Q3 2026 Portfolio Update
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by Brokerages
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
4 Biotech Stocks to Watch as Potential Takeover Targets
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokerages
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
3 Soaring Stocks That May Have More Upside Ahead
Abivax: Wall Street Catches Up to the Data
Abivax Announces Closing of $920 Million Public Offering
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares